Work loss in patients with rheumatoid arthritis treated with abatacept, rituximab, tocilizumab or TNF inhibitors: a nationwide direct drug-to-drug comparison

Work loss in patients with rheumatoid arthritis treated with abatacept, rituximab, tocilizumab or TNF inhibitors: a nationwide direct drug-to-drug comparison

Objective To compare work loss after starting tumour necrosis factor inhibitors (TNFi), rituximab, abatacept or tocilizumab in patients with rheumatoid arthritis (RA).Methods We used data from the Swedish Rheumatology Quality Register to identify patients aged 19-62 years who were treated with TNFi...

Full description

Saved in:
Bibliographic Details
Main Authors: Ulf Lindström, Johan Askling, Katerina Chatzidionysiou, Lotta Ljung, Lars Klareskog, Martin Neovius, Nils Feltelius, Eva Baecklund, Christopher Sjöwall, Helena Forsblad-d’Elia, Carl Turesson, Elisabet Lindqvist, Thomas Frisell, Alf Kastbom, Helena Forsblad-d'Elia, Jonas Söderling, Ann Knight, Gerd-Marie Alenius, Gustaf Magnus Bruze
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/11/1/e004936.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://rmdopen.bmj.com/content/11/1/e004936.full

Similar Items